Vanda Pharmaceuticals Inc.

Sandra Smieszek

Mihael Hristos Polymeropoulos

Gunther Birznieks

Changfu Xiao

Andrew Heitman

The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

Method of improving sleep

The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.

Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone

The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.

Method of treatment of schizophrenia

The disclosure relates to improved methods of treatment of atopic dermatitis and symptoms thereof with tradipitant.

Treatment of atopic dermatitis with tradipitant

The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

Growing community of inventors

Cleveland, OH, United States of America

Sandra Smieszek